Zevra Therapeutics (NASDAQ:ZVRA) Share Price Breaks Above Two Hundred Day Moving Average – Time to Sell?

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $10.76 and traded as high as $11.19. Zevra Therapeutics shares last traded at $11.17, with a volume of 2,064,533 shares.

Key Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q3 2026 revenue rose 45% year over year to $37.8 million, including $34.0 million from MIPLYFFA. Earnings also beat analyst estimates, and the company marked a fourth consecutive quarterly earnings beat. Zevra Q3 financial results and corporate update Zevra beats Q3 estimates for fourth straight quarter
• Positive Sentiment: Zevra expects to file a supplemental new drug application for MIPLYFFA in Q1 2027, a potential future growth opportunity. Zevra anticipates filing MIPLYFFA sNDA in Q1 2027
• Neutral Sentiment: A European CHMP opinion on MIPLYFFA remains expected in Q4; the regulatory outcome is still pending. Regulatory timeline update

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ZVRA shares. HC Wainwright restated a “buy” rating and issued a $26.00 price objective on shares of Zevra Therapeutics in a research note on Thursday, August 20th. UBS Group reiterated a “buy” rating on shares of Zevra Therapeutics in a research report on Thursday, August 20th. Weiss Ratings reissued a “hold (c)” rating on shares of Zevra Therapeutics in a report on Wednesday, August 19th. Guggenheim dropped their target price on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Finally, William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $27.14.

Zevra Therapeutics Stock Performance

The firm has a market cap of $663.27 million, a price-to-earnings ratio of 9.39 and a beta of 1.01. The stock has a 50-day moving average of $11.10 and a 200-day moving average of $10.76.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a return on equity of 57.91% and a net margin of 52.80%. Sell-side analysts predict that Zevra Therapeutics, Inc. will post 0.72 EPS for the current fiscal year.

Insider Transactions at Zevra Therapeutics

In related news, Director Corey Watton sold 12,300 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $11.25, for a total value of $138,375.00. Following the completion of the sale, the director directly owned 1,800 shares in the company, valued at approximately $20,250. The trade was a 87.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Neil F. Mcfarlane sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the transaction, the chief executive officer owned 417,225 shares of the company’s stock, valued at $4,693,781.25. The trade was a 4.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Fulcrum Asset Management LLP bought a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at about $31,000. Alps Advisors Inc. bought a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at $528,000. Integrity Alliance LLC. bought a new stake in Zevra Therapeutics during the third quarter valued at $10,292,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Zevra Therapeutics during the 3rd quarter worth about $33,000. Finally, Profund Advisors LLC lifted its stake in shares of Zevra Therapeutics by 605.6% in the 3rd quarter. Profund Advisors LLC now owns 109,547 shares of the company’s stock valued at $1,202,000 after purchasing an additional 94,021 shares during the period. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.